4/15
04:15 pm
otlk
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
Medium
Report
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
3/31
09:29 am
otlk
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval [Seeking Alpha]
High
Report
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval [Seeking Alpha]
3/27
08:00 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.
3/25
08:45 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target raised by analysts at HC Wainwright from $1.50 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target raised by analysts at HC Wainwright from $1.50 to $30.00. They now have a "buy" rating on the stock.
3/22
08:34 am
otlk
Outlook Therapeutics stock jumps on positive EU CHMP opinion for its wet AMD treatment [Seeking Alpha]
High
Report
Outlook Therapeutics stock jumps on positive EU CHMP opinion for its wet AMD treatment [Seeking Alpha]
3/22
07:44 am
otlk
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD [Yahoo! Finance]
3/22
07:35 am
otlk
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
High
Report
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
3/18
05:14 pm
otlk
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million [Yahoo! Finance]
3/18
05:10 pm
otlk
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
Medium
Report
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
3/12
08:09 am
otlk
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split [Yahoo! Finance]
3/12
08:05 am
otlk
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
High
Report
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
2/22
06:44 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "overweight" rating re-affirmed by analysts at Capital One Financial Co..
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "overweight" rating re-affirmed by analysts at Capital One Financial Co..
2/15
08:00 am
otlk
Kaskela Law LLC Announces Shareholder Investigation of Outlook Therapeutics, Inc. (OTLK) and Encourages Investors to Contact the Firm
Medium
Report
Kaskela Law LLC Announces Shareholder Investigation of Outlook Therapeutics, Inc. (OTLK) and Encourages Investors to Contact the Firm
2/15
07:19 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $3.00 price target on the stock.
High
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $3.00 price target on the stock.
2/14
05:44 pm
otlk
Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments [Yahoo! Finance]
High
Report
Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments [Yahoo! Finance]
2/14
08:10 am
otlk
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update [Yahoo! Finance]
Low
Report
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update [Yahoo! Finance]
2/14
08:05 am
otlk
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
Low
Report
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
1/31
08:19 am
otlk
Outlook Therapeutics® Doses First Subject in NORSE EIGHT [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® Doses First Subject in NORSE EIGHT [Yahoo! Finance]
1/31
08:15 am
otlk
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Outlook Therapeutics, Inc. (NASDAQ: OTLK) and Encourages Investors to Contact the Firm
Medium
Report
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Outlook Therapeutics, Inc. (NASDAQ: OTLK) and Encourages Investors to Contact the Firm
1/31
08:05 am
otlk
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
Medium
Report
Outlook Therapeutics® Doses First Subject in NORSE EIGHT